TCRT — Alaunos Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1107421 ·
Last close
$1.09
Market Cap
$2.77M
52W High
$4.59
52W Low
$1.02
ADV30
1,658,077
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -952,000 | -952,000 | 1,516,000 | 124,000 | 864,000 |
| Mar 2026 | 0 | — | -1,012,000 | -1,006,000 | 1,883,000 | 354,000 | 595,000 |
| Dec 2025 | 3,000 | — | -907,000 | -893,000 | 2,966,000 | 1,385,000 | 813,000 |
| Sep 2025 | 0 | — | -1,187,000 | -1,159,000 | 3,724,000 | 1,938,000 | 921,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-3,128,000
Investing CF
$-1,000
Financing CF
$0
CapEx
$-1,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-2.44
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-925,628,000
Inventory
—
Receivables
$0
ST Investments
—
EBIT TTM
$-4,145,000
Pretax Income TTM
$-4,109,000
Interest Exp TTM
$0
Analysts
—
Yahoo Snapshot (yfinance, live)
Total Revenue
$3,000
EBITDA
$-4,034,000
Free Cash Flow
$-1,570,625
Enterprise Value
$3,712,124
Total Cash
$124,000
Total Debt
$0
Shares Out
2,540,480
Trailing EPS
$-1.75
Book Value
$0.54
ROE
-185.9%
ROA
-81.1%
Div Yield
—
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 5,000 | -4,225,000 | -4,176,000 | 2,966,000 | 813,000 | 2,153,000 | -2,869,000 |
| Dec 2024 | 10,000 | -4,812,000 | -4,679,000 | 2,755,000 | 692,000 | 2,063,000 | -4,971,000 |
| Dec 2023 | 5,000 | -28,493,000 | -35,140,000 | 8,263,000 | 1,956,000 | 6,307,000 | -30,142,000 |
| Dec 2022 | 2,922,000 | -35,238,000 | -37,730,000 | 64,937,000 | 26,382,000 | 38,555,000 | -29,232,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.60
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ISCO | International Stem Cell CORP | $2.80M | $0.35 | — |
| GNPX | Genprex, Inc. | $2.70M | $3.29 | — |
| VBIO | Valion Bio, Inc. | $2.69M | $3.03 | — |
| CASIF | CASI Pharmaceuticals, Inc. | $2.67M | $0.13 | — |
| VCNX | VACCINEX, INC. | $2.60M | $0.97 | — |
News headlines (Yahoo Finance, 1h cache)
Alaunos Reports New Preclinical ALN1003 Data Showing Lower Liver Weight After Adjustment for Body Fat Percentage in 48-Day DIO Mouse Study
2026-06-29 12:35 · Yahoo
Alaunos Reports Positive Preclinical Obesity Drug Results Across Weight, Liver, Insulin Markers
2026-05-26 18:05 · Yahoo
Alaunos Reports Broad Metabolic Improvements with ALN1003 in Obese Mouse Studies
2026-05-26 15:01 · Yahoo
Alaunos Reports Preclinical ALN1003 Data Showing Effects on Insulin-Resistance-Related Biomarkers and Liver Histology in Diet-Induced Obesity Models
2026-05-18 12:00 · Yahoo
Valion Bio Appoints Melinda Lackey as General Counsel
2026-05-04 20:05 · Yahoo
Alaunos Therapeutics, Inc. Announces Pricing of Registered Direct Offering priced at-the-market under Nasdaq rules
2026-09-18 13:00 · Yahoo
Alaunos Therapeutics Announces Positive Preclinical Proof-of-Concept Data for ALN1003, a Differentiated Non-Hormonal Oral Treatment for Obesity and Related Metabolic Disorders
2026-03-02 11:30 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.